biostudies-literatureLiu LDShanghai Science and Technology CommitteeNational Key R&D Program of ChinaNational Natural Science Foundation of ChinaShanghai Jiao Tong University COVID-19980-986https://www.ebi.ac.uk/biostudies/studies/S-EPMC7799018biostudies-literatureUnknown12(12)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common featuJournal of molecular cell biologyThe development of neutralizing antibodies against SARS-CoV-2 and their common features.PMC7799018204907602008186113801481622022319708802017YFA05067008167163431722020Yeap LSMeng FLLian CLiu LDfalseThe development of neutralizing antibodies against SARS-CoV-2 and their common features.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common featu2020-01-01T00:00:00Z2020 Nov2026-04-13T03:07:04.346Z2025-04-05T18:57:05.935ZS-EPMC77990183337792810.1093/jmcb/mjaa070